A classic example of the use of synthetic lethality in cancer therapy is the development of poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of cancer patients carrying mutations in BRCA1/2 tumor-suppressor genes (3). The gene discussed is BRCA1; the disease is neoplasm.